INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7201, 'Formoterol', 'Astemizole', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7205/', '', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, More', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Bitolterol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7202, 'Formoterol', 'Atenolol', 'Moderate', 'Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in patients with asthma or other obstructive airway diseases. Cardioselective beta-blockers can occasionally precipitate acute bronchospasm in these patients, despite relative selectivity for beta-1 receptors in cardiac tissues. Presumably, beta-1 selectivity is dose-dependent and may be lost given a sufficient dose of the beta-blocker in susceptible patients. Other mechanisms may also be involved in bronchoconstriction that are unrelated to beta-2 blockade--for example, their effects on cholinergic M2 receptors and alpha-1 adrenoreceptors.', 'DDInter', 'Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases. However, given their demonstrated benefit in such conditions as heart failure, myocardial infarction, cardiac arrhythmias and hypertension, cardioselective beta-blockers may be administered with caution to those who do not respond to or tolerate alternative treatment. The benefits generally outweigh the risks in patients with mild or moderate reactive airway disease that is well controlled on inhaled corticosteroids and beta-2 agonists, provided they have no prior history suggesting a predisposition to severe exacerbations.', 'Others', 'Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7206/', '', 'Nifedipine', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Cromoglicic acid, Ipratropium, Beclomethasone dipropionate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7203, 'Formoterol', 'Atomoxetine', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', 'DDInter', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7207/', '', 'Pemoline, Citicoline, Caffeine', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7204, 'Formoterol', 'Azithromycin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7208/', '', 'Tinidazole, Tetracycline, Cefepime, Metronidazole, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Netilmicin, More', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Beclomethasone dipropionate, Ephedrine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7205, 'Formoterol', 'Beclomethasone dipropionate', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7209/', '', 'Fluocinolone acetonide, Clobetasol, Fluocinonide, Fluorometholone, Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Cromoglicic acid, Ipratropium, Formoterol, More', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Bitolterol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7206, 'Formoterol', 'Bedaquiline', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7210/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More', 'Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7207, 'Formoterol', 'Bendroflumethiazide', 'Moderate', 'Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.', 'DDInter', 'Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.', 'Synergism', 'Caution is advised when beta-2 agonists are used with potassium-wasting diuretics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7211/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Isoprenaline, Ephedrine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7208, 'Formoterol', 'Benzphetamine', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', 'DDInter', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7212/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7209, 'Formoterol', 'Benzthiazide', 'Moderate', 'Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.', 'DDInter', 'Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.', 'Synergism', 'Caution is advised when beta-2 agonists are used with potassium-wasting diuretics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7213/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Bitolterol, Isoprenaline, Tiotropium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7210, 'Formoterol', 'Bepridil', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7214/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Bitolterol, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7211, 'Formoterol', 'Betamethasone', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7215/', '', 'Mupirocin, Mometasone furoate, Vitamin A, Olopatadine, Cromoglicic acid, Ipratropium, Hyaluronic acid, Nedocromil, Fluocinolone acetonide, Hydrocortisone butyrate, Salicylic acid, More', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Olodaterol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7212, 'Formoterol', 'Betaxolol', 'Moderate', 'Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in patients with asthma or other obstructive airway diseases. Cardioselective beta-blockers can occasionally precipitate acute bronchospasm in these patients, despite relative selectivity for beta-1 receptors in cardiac tissues. Presumably, beta-1 selectivity is dose-dependent and may be lost given a sufficient dose of the beta-blocker in susceptible patients. Other mechanisms may also be involved in bronchoconstriction that are unrelated to beta-2 blockade--for example, their effects on cholinergic M2 receptors and alpha-1 adrenoreceptors.', 'DDInter', 'Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases. However, given their demonstrated benefit in such conditions as heart failure, myocardial infarction, cardiac arrhythmias and hypertension, cardioselective beta-blockers may be administered with caution to those who do not respond to or tolerate alternative treatment. The benefits generally outweigh the risks in patients with mild or moderate reactive airway disease that is well controlled on inhaled corticosteroids and beta-2 agonists, provided they have no prior history suggesting a predisposition to severe exacerbations.', 'Others', 'Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7216/', '', 'Latanoprost, Apraclonidine, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Guanethidine, Levobunolol', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7213, 'Formoterol', 'Betaxolol (ophthalmic)', 'Moderate', 'Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in patients with asthma or other obstructive airway diseases. Cardioselective beta-blockers can occasionally precipitate acute bronchospasm in these patients, despite relative selectivity for beta-1 receptors in cardiac tissues. Presumably, beta-1 selectivity is dose-dependent and may be lost given a sufficient dose of the beta-blocker in susceptible patients. Other mechanisms may also be involved in bronchoconstriction that are unrelated to beta-2 blockade--for example, their effects on cholinergic M2 receptors and alpha-1 adrenoreceptors.', 'DDInter', 'Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases. However, given their demonstrated benefit in such conditions as heart failure, myocardial infarction, cardiac arrhythmias and hypertension, cardioselective beta-blockers may be administered with caution to those who do not respond to or tolerate alternative treatment. The benefits generally outweigh the risks in patients with mild or moderate reactive airway disease that is well controlled on inhaled corticosteroids and beta-2 agonists, provided they have no prior history suggesting a predisposition to severe exacerbations.', 'Others', 'Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7217/', '', 'Latanoprost, Apraclonidine, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Guanethidine, Levobunolol', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7214, 'Formoterol', 'Bicalutamide', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7218/', '', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate, Ephedrine', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane, Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7215, 'Formoterol', 'Bisoprolol', 'Moderate', 'Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in patients with asthma or other obstructive airway diseases. Cardioselective beta-blockers can occasionally precipitate acute bronchospasm in these patients, despite relative selectivity for beta-1 receptors in cardiac tissues. Presumably, beta-1 selectivity is dose-dependent and may be lost given a sufficient dose of the beta-blocker in susceptible patients. Other mechanisms may also be involved in bronchoconstriction that are unrelated to beta-2 blockade--for example, their effects on cholinergic M2 receptors and alpha-1 adrenoreceptors.', 'DDInter', 'Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases. However, given their demonstrated benefit in such conditions as heart failure, myocardial infarction, cardiac arrhythmias and hypertension, cardioselective beta-blockers may be administered with caution to those who do not respond to or tolerate alternative treatment. The benefits generally outweigh the risks in patients with mild or moderate reactive airway disease that is well controlled on inhaled corticosteroids and beta-2 agonists, provided they have no prior history suggesting a predisposition to severe exacerbations.', 'Others', 'Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7219/', '', 'Nifedipine, Moexipril, Perindopril, Benazepril, Quinapril, Trandolapril, Fosinopril', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Cromoglicic acid, Ipratropium, Beclomethasone dipropionate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7216, 'Formoterol', 'Bosutinib', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7220/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More', 'Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7217, 'Formoterol', 'Budesonide', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7221/', '', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Budesonide, Mometasone, Ipratropium, Olodaterol, Beclomethasone dipropionate, Ephedrine', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Cromoglicic acid, Ipratropium, Formoterol, Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7218, 'Formoterol', 'Bumetanide', 'Moderate', 'Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.', 'DDInter', 'Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.', 'Synergism', 'Caution is advised when beta-2 agonists are used with potassium-wasting diuretics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7222/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Isoprenaline, Isoprenaline, Ephedrine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7219, 'Formoterol', 'Buprenorphine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7223/', '', 'Diamorphine, Acamprosate, Naltrexone, Disulfiram, Nalmefene, Codeine, Naltrexone, Oxymorphone, Oxycodone, Butorphanol, Meperidine, More', 'Mometasone furoate, Umeclidinium, Budesonide, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate, Ephedrine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7220, 'Formoterol', 'Cabozantinib', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7224/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More', 'Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7221, 'Formoterol', 'Canagliflozin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7225/', '', 'Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Pirbuterol, Bitolterol, Tiotropium, More', 'Pramlintide, Tolazamide, Acetohexamide, Guar gum', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7222, 'Formoterol', 'Carteolol', 'Major', 'Beta-blockers may antagonize the effects of beta-2 adrenergic bronchodilators and precipitate acute, life-threatening bronchospasm in patients with asthma or other obstructive airway diseases. The mechanism involves increased airway resistance and reduced bronchodilation due to blockade of beta-2 adrenergic receptors. The interaction may also occur with ophthalmically applied beta-blockers, which are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels. Due to opposing effects on beta-2 adrenergic receptors, propranolol has been used in the treatment of albuterol overdose. Likewise, beta-2 adrenergic agonists may interfere with the pharmacologic effects of beta-blockers.', 'DDInter', 'Concomitant use of beta-2 adrenergic bronchodilators with beta-blockers, including ophthalmic formulations, should generally be avoided. If coadministration is required, a cardioselective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol) is usually preferred. Nevertheless, caution is advised and respiratory status should be closely monitored, as cardioselectivity is not absolute and larger doses of beta-1 selective agents may pose some of the same risks as nonselective agents. In general, nonselective beta-blockers are considered contraindicated in patients with obstructive airways disease.', 'Antagonism', 'Concomitant use of beta-2 adrenergic bronchodilators with beta-blockers, including ophthalmic formulations, should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7226/', '', 'Latanoprost, Apraclonidine, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Guanethidine, Levobunolol', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Bitolterol, Tiotropium, Beclomethasone dipropionate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7223, 'Formoterol', 'Carteolol (ophthalmic)', 'Major', 'Beta-blockers may antagonize the effects of beta-2 adrenergic bronchodilators and precipitate acute, life-threatening bronchospasm in patients with asthma or other obstructive airway diseases. The mechanism involves increased airway resistance and reduced bronchodilation due to blockade of beta-2 adrenergic receptors. The interaction may also occur with ophthalmically applied beta-blockers, which are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels. Due to opposing effects on beta-2 adrenergic receptors, propranolol has been used in the treatment of albuterol overdose. Likewise, beta-2 adrenergic agonists may interfere with the pharmacologic effects of beta-blockers.', 'DDInter', 'Concomitant use of beta-2 adrenergic bronchodilators with beta-blockers, including ophthalmic formulations, should generally be avoided. If coadministration is required, a cardioselective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol) is usually preferred. Nevertheless, caution is advised and respiratory status should be closely monitored, as cardioselectivity is not absolute and larger doses of beta-1 selective agents may pose some of the same risks as nonselective agents. In general, nonselective beta-blockers are considered contraindicated in patients with obstructive airways disease.', 'Antagonism', 'Concomitant use of beta-2 adrenergic bronchodilators with beta-blockers, including ophthalmic formulations, should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7227/', '', 'Latanoprost, Apraclonidine, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Guanethidine, Levobunolol', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7224, 'Formoterol', 'Carvedilol', 'Major', 'Beta-blockers may antagonize the effects of beta-2 adrenergic bronchodilators and precipitate acute, life-threatening bronchospasm in patients with asthma or other obstructive airway diseases. The mechanism involves increased airway resistance and reduced bronchodilation due to blockade of beta-2 adrenergic receptors. The interaction may also occur with ophthalmically applied beta-blockers, which are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels. Due to opposing effects on beta-2 adrenergic receptors, propranolol has been used in the treatment of albuterol overdose. Likewise, beta-2 adrenergic agonists may interfere with the pharmacologic effects of beta-blockers.', 'DDInter', 'Concomitant use of beta-2 adrenergic bronchodilators with beta-blockers, including ophthalmic formulations, should generally be avoided. If coadministration is required, a cardioselective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol) is usually preferred. Nevertheless, caution is advised and respiratory status should be closely monitored, as cardioselectivity is not absolute and larger doses of beta-1 selective agents may pose some of the same risks as nonselective agents. In general, nonselective beta-blockers are considered contraindicated in patients with obstructive airways disease.', 'Antagonism', 'Concomitant use of beta-2 adrenergic bronchodilators with beta-blockers, including ophthalmic formulations, should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7228/', '', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Cromoglicic acid, Ipratropium, Beclomethasone dipropionate', 'Nifedipine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7225, 'Formoterol', 'Ceritinib', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7229/', '', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Epinephrine, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate, Ephedrine', 'Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7226, 'Formoterol', 'Chloroquine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7230/', '', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7227, 'Formoterol', 'Chlorothiazide', 'Moderate', 'Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.', 'DDInter', 'Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.', 'Synergism', 'Caution is advised when beta-2 agonists are used with potassium-wasting diuretics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7231/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Epinephrine, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Isoprenaline, Ephedrine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7228, 'Formoterol', 'Chlorpromazine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7232/', '', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Mometasone, Mometasone furoate, Beclomethasone dipropionate, Cromoglicic acid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7229, 'Formoterol', 'Chlorpropamide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7233/', '', 'Pramlintide, Tolazamide, Acetohexamide, Guar gum', 'Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Pirbuterol, Bitolterol, Olodaterol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7230, 'Formoterol', 'Chlorthalidone', 'Moderate', 'Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.', 'DDInter', 'Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.', 'Synergism', 'Caution is advised when beta-2 agonists are used with potassium-wasting diuretics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7234/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Epinephrine, Cromoglicic acid, Ipratropium, Isoprenaline, Isoprenaline, Ephedrine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7231, 'Formoterol', 'Ciclesonide', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7235/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Olodaterol, Epinephrine, More', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Ipratropium, Cromoglicic acid, Revefenacin, Nedocromil, Mupirocin, Mometasone furoate, Vitamin A, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7232, 'Formoterol', 'Ciprofloxacin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7236/', '', 'Tinidazole, Tetracycline, Cefepime, Metronidazole, Secnidazole, Cefixime, Amikacin, Tetracycline, Polymyxin B, Chloramphenicol, Gentamicin, More', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Beclomethasone dipropionate, Ephedrine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7233, 'Formoterol', 'Cisapride', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7237/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate, Ephedrine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7234, 'Formoterol', 'Citalopram', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7238/', '', 'St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Beclomethasone dipropionate, Ephedrine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7235, 'Formoterol', 'Clarithromycin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7239/', '', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Ipratropium, Beclomethasone dipropionate, Ephedrine', 'Tinidazole, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7236, 'Formoterol', 'Clofazimine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7240/', '', 'Dapsone', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7237, 'Formoterol', 'Clomipramine', 'Moderate', 'Concomitant use of beta-2 adrenergic agonists with tricyclic antidepressants (TCAs) may increase the risk and/or severity of cardiovascular adverse effects such as hypertension, palpitation, chest pain, and arrhythmia.', 'DDInter', 'Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter. Cardiovascular status should be closely monitored.', 'Synergism', 'Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7241/', '', 'Mometasone furoate, Budesonide, Mometasone, Fluticasone, Cromoglicic acid, Beclomethasone dipropionate', 'St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7238, 'Formoterol', 'Clozapine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7242/', '', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Mometasone, Mometasone furoate, Beclomethasone dipropionate, Cromoglicic acid, Ephedrine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7239, 'Formoterol', 'Cocaine (nasal)', 'Major', 'Concomitant use of cocaine with sympathomimetic agents such as epinephrine and phenylephrine may lead to additive cardiovascular effects. The proposed mechanism involves increased circulating catecholamines and increased activity of the sympathetic nervous system.', 'DDInter', 'Concomitant use of cocaine with sympathomimetic agents should be avoided. If coadministration is required, prolonged vital sign and ECG monitoring may be necessary.', 'Synergism', 'Concomitant use of cocaine with sympathomimetic agents should be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7243/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7240, 'Formoterol', 'Cocaine (topical)', 'Major', 'Concomitant use of cocaine with sympathomimetic agents such as epinephrine and phenylephrine may lead to additive cardiovascular effects. The proposed mechanism involves increased circulating catecholamines and increased activity of the sympathetic nervous system.', 'DDInter', 'Concomitant use of cocaine with sympathomimetic agents should be avoided. If coadministration is required, prolonged vital sign and ECG monitoring may be necessary.', 'Synergism', 'Concomitant use of cocaine with sympathomimetic agents should be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7244/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7241, 'Formoterol', 'Corticotropin', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7245/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Olodaterol, More', 'Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Mecasermin rinfabate, Pegvisomant, Somapacitan', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7242, 'Formoterol', 'Tetracosactide', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7246/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Olodaterol, More', 'Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Mecasermin rinfabate, Pegvisomant, Somapacitan', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7243, 'Formoterol', 'Crizotinib', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7247/', '', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Epinephrine, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate, Ephedrine', 'Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7244, 'Formoterol', 'Dapagliflozin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7248/', '', 'Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Pirbuterol, Bitolterol, Olodaterol, More', 'Pramlintide, Tolazamide, Acetohexamide, Guar gum', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7245, 'Formoterol', 'Dasatinib', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7249/', '', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Epinephrine, Beclomethasone dipropionate, Ephedrine', 'Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7246, 'Formoterol', 'Daunorubicin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7250/', '', 'Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin, Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, More', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7247, 'Formoterol', 'Daunorubicin (liposomal)', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7251/', '', 'Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin, Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, More', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Bitolterol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7248, 'Formoterol', 'Degarelix', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7252/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7249, 'Formoterol', 'Desipramine', 'Moderate', 'Concomitant use of beta-2 adrenergic agonists with tricyclic antidepressants (TCAs) may increase the risk and/or severity of cardiovascular adverse effects such as hypertension, palpitation, chest pain, and arrhythmia.', 'DDInter', 'Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter. Cardiovascular status should be closely monitored.', 'Synergism', 'Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7253/', '', 'Mometasone furoate, Budesonide, Mometasone, Fluticasone, Cromoglicic acid, Beclomethasone dipropionate', 'St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7250, 'Formoterol', 'Desvenlafaxine', 'Moderate', 'Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors. The use of SNRIs alone has been associated with sustained increases in blood pressure and heart rate, and cases of elevated blood pressure requiring immediate treatment have been reported in postmarketing experience.', 'DDInter', 'Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate. Blood pressure and pulse should be measured prior to initiating SNRI therapy and monitored at regular intervals thereafter. Dose reduction or discontinuation of the SNRI should be considered in patients who experience a sustained increase in blood pressure or pulse rate.', 'Synergism', 'Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7254/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', 'St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7251, 'Formoterol', 'Deutetrabenazine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7255/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More', 'Dextromethorphan, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7252, 'Formoterol', 'Dexamethasone', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7256/', '', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Olodaterol, Beclomethasone dipropionate', 'Mupirocin, Mometasone furoate, Vitamin A, Olopatadine, Cromoglicic acid, Ipratropium, Hyaluronic acid, Nedocromil, Mometasone furoate, Fluorometholone, Minocycline, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7253, 'Formoterol', 'Dexmethylphenidate', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', 'DDInter', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7257/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', 'Pemoline, Citicoline, Caffeine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7254, 'Formoterol', 'Dextroamphetamine', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', 'DDInter', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7258/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', 'Pemoline, Citicoline, Caffeine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7255, 'Formoterol', 'Diclofenamide', 'Moderate', 'Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.', 'DDInter', 'Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.', 'Synergism', 'Caution is advised when beta-2 agonists are used with potassium-wasting diuretics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7259/', '', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, More', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7256, 'Formoterol', 'Diethylpropion', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', 'DDInter', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7260/', '', 'Dexfenfluramine, Lorcaserin, Orlistat, Naltrexone', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7257, 'Formoterol', 'Dipivefrin (ophthalmic)', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', 'DDInter', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7261/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7258, 'Formoterol', 'Disopyramide', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7262/', '', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', 'Mometasone furoate, Mometasone, Fluticasone, Cromoglicic acid, Epinephrine, Beclomethasone dipropionate, Ephedrine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7259, 'Formoterol', 'Dobutamine', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', 'DDInter', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7263/', '', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate, Ephedrine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7260, 'Formoterol', 'Dofetilide', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7264/', '', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Epinephrine, Beclomethasone dipropionate, Ephedrine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7261, 'Formoterol', 'Dolasetron', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7265/', '', 'Nabilone, Scopolamine, Rolapitant, Aprepitant, Dronabinol', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Epinephrine, Beclomethasone dipropionate, Ephedrine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7262, 'Formoterol', 'Dopamine', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', 'DDInter', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7266/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7263, 'Formoterol', 'Doxapram', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', 'DDInter', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7267/', '', 'Nitric Oxide, Ivacaftor, Elexacaftor, Lumacaftor', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7264, 'Formoterol', 'Doxepin', 'Moderate', 'Concomitant use of beta-2 adrenergic agonists with tricyclic antidepressants (TCAs) may increase the risk and/or severity of cardiovascular adverse effects such as hypertension, palpitation, chest pain, and arrhythmia.', 'DDInter', 'Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter. Cardiovascular status should be closely monitored.', 'Synergism', 'Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7268/', '', 'Mometasone, Mometasone furoate, Beclomethasone dipropionate, Cromoglicic acid', 'St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine, Lidocaine, Clemastine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7265, 'Formoterol', 'Doxepin (topical)', 'Moderate', 'Concomitant use of beta-2 adrenergic agonists with tricyclic antidepressants (TCAs) may increase the risk and/or severity of cardiovascular adverse effects such as hypertension, palpitation, chest pain, and arrhythmia.', 'DDInter', 'Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter. Cardiovascular status should be closely monitored.', 'Synergism', 'Caution is advised if beta-2 agonists are used with TCAs, or within two weeks of discontinuing the latter.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7269/', '', 'Mometasone furoate, Budesonide, Mometasone, Fluticasone, Cromoglicic acid, Epinephrine, Beclomethasone dipropionate, Ephedrine', 'St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine, Lidocaine, Clemastine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7266, 'Formoterol', 'Doxorubicin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7270/', '', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Beclomethasone dipropionate, Ephedrine', 'Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7267, 'Formoterol', 'Doxorubicin (liposomal)', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7271/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Bitolterol, More', 'Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7268, 'Formoterol', 'Dronedarone', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7272/', '', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Epinephrine, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate, Ephedrine', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7269, 'Formoterol', 'Droperidol', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7273/', '', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate, Ephedrine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7270, 'Formoterol', 'Droxidopa', 'Moderate', 'Agents that increase blood pressure such as vasopressors, triptans, decongestants, beta-2 agonists, and amphetamines may potentiate the risk of supine hypertension associated with the use of droxidopa in the treatment of neurogenic orthostatic hypotension.', 'DDInter', 'Supine blood pressure should be monitored prior to and during droxidopa treatment, and more frequently when increasing dosage. Patients should elevate the head of the bed when resting or sleeping, and have blood pressure also measured in this position. Dosage reduction or discontinuation of droxidopa is recommended if supine hypertension cannot be managed by elevation of the head of the bed. Supine hypertension that is not well managed may increase the risk of cardiovascular events, particularly stroke.', 'Synergism', 'Supine blood pressure should be monitored prior to and during droxidopa treatment, and more frequently when increasing dosage.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7274/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Olodaterol, Tiotropium, Beclomethasone dipropionate', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7271, 'Formoterol', 'Dulaglutide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7275/', '', 'Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Pirbuterol, Bitolterol, Olodaterol, More', 'Pramlintide, Tolazamide, Acetohexamide, Guar gum', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7272, 'Formoterol', 'Duloxetine', 'Moderate', 'Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors. The use of SNRIs alone has been associated with sustained increases in blood pressure and heart rate, and cases of elevated blood pressure requiring immediate treatment have been reported in postmarketing experience.', 'DDInter', 'Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate. Blood pressure and pulse should be measured prior to initiating SNRI therapy and monitored at regular intervals thereafter. Dose reduction or discontinuation of the SNRI should be considered in patients who experience a sustained increase in blood pressure or pulse rate.', 'Synergism', 'Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7276/', '', 'St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Beclomethasone dipropionate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7273, 'Formoterol', 'Dyphylline', 'Moderate', 'Concomitant use of beta-2 adrenergic agonists with theophylline may increase the risk and/or severity of hypokalemia and adverse cardiovascular effects such as palpitation, tachycardia, and blood pressure elevation. Adverse events, especially hypokalemia, may be more likely with systemic or nebulized formulations of beta-2 agonists or high dosages of theophylline. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations, while hypokalemia associated with theophylline often occurs in toxicity. Pharmacokinetically, some beta-2 agonists given systemically may decrease the plasma concentrations of theophylline.', 'DDInter', 'Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer. Close monitoring is particularly important in patients with severe asthma, since the potential increases in blood pressure and heart rate may have more serious consequences in the presence of hypoxemia or hypercapnia due to increased myocardial oxygen consumption. Patients should be advised to notify their physician if they experience worsening of their respiratory condition or potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.', 'Synergism', 'Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7277/', '', 'Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7274, 'Formoterol', 'Efavirenz', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7278/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Epinephrine, Beclomethasone dipropionate, Ephedrine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7275, 'Formoterol', 'Empagliflozin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7279/', '', 'Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Pirbuterol, Bitolterol, Olodaterol, More', 'Pramlintide, Tolazamide, Acetohexamide, Guar gum', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7276, 'Formoterol', 'Encorafenib', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7280/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More', 'Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7277, 'Formoterol', 'Entrectinib', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7281/', '', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate, Ephedrine', 'Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7278, 'Formoterol', 'Enzalutamide', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7282/', '', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Epinephrine, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate, Ephedrine', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7279, 'Formoterol', 'Ephedrine', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', 'DDInter', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7283/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More', 'Ketorolac, Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Mupirocin, Mometasone furoate, Vitamin A, Olopatadine, Cromoglicic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7280, 'Formoterol', 'Ephedrine (nasal)', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', 'DDInter', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7284/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Bitolterol, More', 'Ketorolac, Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Mupirocin, Mometasone furoate, Vitamin A, Olopatadine, Cromoglicic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7281, 'Formoterol', 'Epinephrine', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', 'DDInter', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7285/', '', 'Tetracycline, Minocycline, Amphotericin B, Miconazole, Metronidazole, Neomycin, Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Cromoglicic acid, More', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Epinephrine, Beclomethasone dipropionate, Ephedrine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7282, 'Formoterol', 'Epinephrine (ophthalmic)', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', 'DDInter', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7286/', '', 'Tetracycline, Minocycline, Amphotericin B, Miconazole, Metronidazole, Neomycin, Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Cromoglicic acid, More', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7283, 'Formoterol', 'Epinephrine (topical)', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', 'DDInter', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7287/', '', 'Tetracycline, Minocycline, Amphotericin B, Miconazole, Metronidazole, Neomycin, Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Cromoglicic acid, More', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Bitolterol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7284, 'Formoterol', 'Epirubicin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7288/', '', 'Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7285, 'Formoterol', 'Eribulin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7289/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7286, 'Formoterol', 'Ertugliflozin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7290/', '', 'Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Pirbuterol, Bitolterol, Tiotropium, More', 'Pramlintide, Tolazamide, Acetohexamide, Guar gum', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7287, 'Formoterol', 'Erythromycin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7291/', '', 'Dirithromycin, Lincomycin, Troleandomycin, Clindamycin, Minocycline, Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, More', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Ipratropium, Beclomethasone dipropionate, Ephedrine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7288, 'Formoterol', 'Escitalopram', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7292/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More', 'St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7289, 'Formoterol', 'Esmolol', 'Moderate', 'Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in patients with asthma or other obstructive airway diseases. Cardioselective beta-blockers can occasionally precipitate acute bronchospasm in these patients, despite relative selectivity for beta-1 receptors in cardiac tissues. Presumably, beta-1 selectivity is dose-dependent and may be lost given a sufficient dose of the beta-blocker in susceptible patients. Other mechanisms may also be involved in bronchoconstriction that are unrelated to beta-2 blockade--for example, their effects on cholinergic M2 receptors and alpha-1 adrenoreceptors.', 'DDInter', 'Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases. However, given their demonstrated benefit in such conditions as heart failure, myocardial infarction, cardiac arrhythmias and hypertension, cardioselective beta-blockers may be administered with caution to those who do not respond to or tolerate alternative treatment. The benefits generally outweigh the risks in patients with mild or moderate reactive airway disease that is well controlled on inhaled corticosteroids and beta-2 agonists, provided they have no prior history suggesting a predisposition to severe exacerbations.', 'Others', 'Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7293/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7290, 'Formoterol', 'Etacrynic acid', 'Moderate', 'Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.', 'DDInter', 'Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.', 'Synergism', 'Caution is advised when beta-2 agonists are used with potassium-wasting diuretics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7294/', '', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7291, 'Formoterol', 'Exenatide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7295/', '', 'Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Pirbuterol, Bitolterol, Olodaterol, More', 'Pramlintide, Tolazamide, Acetohexamide, Guar gum', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7292, 'Formoterol', 'Ezogabine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7296/', '', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More', 'Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7293, 'Formoterol', 'Fenfluramine', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', 'DDInter', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7297/', '', 'Dexfenfluramine, Lorcaserin, Orlistat, Naltrexone, Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, More', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7294, 'Formoterol', 'Fingolimod', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7298/', '', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate, Ephedrine', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7295, 'Formoterol', 'Flecainide', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7299/', '', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Epinephrine, Beclomethasone dipropionate, Ephedrine', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7296, 'Formoterol', 'Fluconazole', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7300/', '', 'Tinidazole, Tetracycline, Cefepime, Metronidazole, Secnidazole, Cefixime, Amikacin, Caspofungin, Micafungin, Amphotericin B, Itraconazole, More', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Beclomethasone dipropionate, Ephedrine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7297, 'Formoterol', 'Fludrocortisone', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7301/', '', 'Fluocinolone acetonide, Indomethacin, Fluocinolone acetonide, Fluorometholone, Deflazacort', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Olodaterol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7298, 'Formoterol', 'Flunisolide', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7302/', '', 'Mupirocin, Mometasone furoate, Vitamin A, Olopatadine, Cromoglicic acid, Ipratropium, Hyaluronic acid, Nedocromil, Mometasone furoate, Umeclidinium, Aclidinium, More', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Olodaterol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7299, 'Formoterol', 'Fluoxetine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7303/', '', 'St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Beclomethasone dipropionate, Ephedrine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (7300, 'Formoterol', 'Fluphenazine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/7304/', '', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Mometasone furoate, Budesonide, Mometasone, Fluticasone, Cromoglicic acid, Beclomethasone dipropionate', 1767369485);
